Elly Mesman

3.4k citations

9 papers · 2.7k indexed · 2 hit papers · h-index 9

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Drug Transport and Resistance Mechanisms
Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 7
- CAR-T cell therapy research 2
- Drug Transport and Resistance Mechanisms 2
- Cancer Immunotherapy and Biomarkers 2
Immunology 4
- Immunotherapy and Immune Responses 4
- Immune Cell Function and Interaction 2

Co-authors: Alexander Griekspoor Joost Neijssen Kevin Camphausen Tom A. Groothuis Frank A. W. Verreck Peter A. van Veelen Hergen Spits Jeffrey Schlom
Journals: The Journal of Cell Biology (1 paper)The Journal of Immunology (1 paper)Nature Medicine (1 paper)The EMBO Journal (1 paper)Clinical Cancer Research (1 paper)
Partner nations: Netherlands United States Italy

In The Last Decade

Elly Mesman

9 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation 2007 · 651 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 The EMBO Journal
2006 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Elly Mesman

Since Specialization

Citations

This map shows the geographic impact of Elly Mesman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elly Mesman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elly Mesman more than expected).

Fields of papers citing papers by Elly Mesman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elly Mesman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elly Mesman. The network helps show where Elly Mesman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Elly Mesman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Elly Mesman Line = papers co-authored together Elly Mesman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work
1	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice Disease Models & Mechanisms ·Patrick W.B. Derksen, Tanya M. Braumuller, Eline van der Burg, Marten Hornsveld, Elly Mesman, Jelle Wesseling, Paul Krimpenfort, Jos Jonkers	2011	101
2	TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation The Journal of Immunology ·Moniek A. de Witte, Gavin Bendle, Marly D. van den Boom, Miriam Coccoris, Todd D. Schell, Satvir S. Tevethia, Harm van Tinteren, Elly Mesman, Ji-Ying Song, Ton N. Schumacher	2008	36
3	Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1) Drug Metabolism and Disposition ·Evita van de Steeg, Cornelia M.M. van der Kruijssen, Els Wagenaar, R.A. Chandler, Elly Mesman, Kathryn E. Kenworthy, Alfred H. Schinkel	2008	97
4	Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation The EMBO Journal ·Carlos le Sage, Remco Nagel, David A. Egan, Mariëtte Schrier, Elly Mesman, Annunziato Mangiola, Svetlana M. Darkina, Giulio Maira, Neri Mercatelli, Silvia Anna Ciafrè, Maria Giulia Farace, Reuven Agami Hit paper breakdown →	2007	651
5	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy The Journal of Experimental Medicine ·Eric A. Reits, James W. Hodge, Carla Herberts, Tom A. Groothuis, Mala Chakraborty, Elizabeth K. Wansley, Kevin Camphausen, Rosalie M. Luiten, Reski Rumondang, Joost Neijssen, Alexander Griekspoor, Elly Mesman, Frank A. W. Verreck, Hergen Spits, Jeffrey Schlom, Peter A. van Veelen, Jacques Neefjes Hit paper breakdown →	2006	1346
6	Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy The Journal of Cell Biology ·Eric A. Reits, James W. Hodge, Carla Herberts, Tom A. Groothuis, Mala Chakraborty, Elizabeth K. Wansley, Kevin Camphausen, Rosalie M. Luiten, Reski Rumondang, Joost Neijssen, Alexander Griekspoor, Elly Mesman, Frank A. W. Verreck, Hergen Spits, Jeffrey Schlom, Peter A. van Veelen, Jacques Neefjes	2006	65
7	Targeting self-antigens through allogeneic TCR gene transfer Blood ·Moniek A. de Witte, Miriam Coccoris, Monika C. Wolkers, Marly D. van den Boom, Elly Mesman, Ji‐Ying Song, Martin van der Valk, John B.A.G. Haanen, Ton N. Schumacher	2006	56
8	Radiosensitization of Squamous Cell Carcinoma by the Alkylphospholipid Perifosine in Cell Culture and Xenografts Clinical Cancer Research ·Stefan R. Vink, Roberto Tetsuo Fujiyama, Elly Mesman, Jan H.M. Schellens, Adrian C. Begg, Wim J. van Blitterswijk, Marcel Verheij	2006	48
9	The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk Nature Medicine ·Johan W. Jonker, Gracia Merino, Le Thi Kim Chung, Antonius E. van Herwaarden, B. Poujardieu, Els Wagenaar, Elly Mesman, Trevor Dale, Alfred H. Schinkel	2005	318

About Elly Mesman

Elly Mesman is a scholar working on Oncology, Immunology, Pediatrics, Perinatology and Child Health, Cancer Research and Molecular Biology, having authored 9 papers that have together received 2.7k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (4 papers), CAR-T cell therapy research (2 papers), Drug Transport and Resistance Mechanisms (2 papers), Pharmacological Effects and Toxicity Studies (2 papers), Immune Cell Function and Interaction (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer therapeutics and mechanisms (1 paper) and RNA modifications and cancer (1 paper). The work is most often cited by research in Oncology (1.6k citations), Immunology (953 citations), Cancer Research (662 citations), Molecular Biology (930 citations) and Pulmonary and Respiratory Medicine (338 citations). Elly Mesman has collaborated with scholars based in Netherlands, United States and Italy. Frequent co-authors include Alexander Griekspoor, Joost Neijssen, Kevin Camphausen, Tom A. Groothuis, Frank A. W. Verreck, Peter A. van Veelen, Hergen Spits, Jeffrey Schlom, Elizabeth K. Wansley and Jacques Neefjes. Their work appears in journals such as The Journal of Cell Biology, The Journal of Immunology, Nature Medicine, The EMBO Journal and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact